Nanocarriers for treating pulmonary inflammation
A nanocarrier system using extracellular vesicles loaded with anti-inflammatory cargo targets specific lung cells to modulate inflammation in ARDS, addressing the lack of effective treatments for this syndrome by improving lung function and reducing cytokine secretion.
Patent Information
- Application Number
- JP2021521287
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-10-19
- Filing Date
- 2019-10-18
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2039-10-18
AI Technical Summary
There are currently no approved treatments for Acute Respiratory Distress Syndrome (ARDS), characterized by severe hypoxemia and diffuse bilateral pulmonary infiltrates, with existing therapies failing to effectively target and modulate lung inflammation.
Development of a nanocarrier system using custom-made extracellular vesicles (EVs) loaded with anti-inflammatory cargo, such as microRNA-146a, and functionalized with ligands to target specific receptors in the lung microenvironment, including pulmonary surfactant protein A (SPA) for type II alveolar epithelial cells and membrane glycoprotein CD200 for lung macrophages, to modulate inflammation.
The nanocarrier system effectively targets and reduces lung inflammation, improving physiological parameters and decreasing inflammatory cytokine secretion, offering a promising therapeutic approach for ARDS.
Smart Images

Figure 0007577335000006 
Figure 0007577335000007 
Figure 0007577335000008
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 62 / 747987, filed October 19, 2018, the entire contents of which are incorporated by reference herein.
[0002] Sequence Listing This application contains a Sequence Listing that has been submitted electronically as an ASCII.txt file titled "321501-2340 Sequence Listing_ST25", created on October 18, 2019. The entire contents of the Sequence Listing are incorporated by reference into this application. [Background technology]
[0003] Acute respiratory distress syndrome (ARDS) is characterized by severe hypoxemia, diffuse bilateral pulmonary infiltrates, and reduced pulmonary compliance. Currently, there are no approved treatments for ARDS. Summary of the Invention [Problem to be solved by the invention]
[0004] Disclosed herein are nanocarrier systems for efficiently targeting lung cells loaded with anti-inflammatory cargo and modulating lung inflammation in ARDS. These nanocarriers are obtained by in vitro cell or in vivo tissue transfection using various transfection techniques (bulk electroporation, nanoelectroporation, tissue nanotransfection, viral transfection, etc.). The disclosed nanocarriers are custom-made extracellular vesicles (EVs) loaded with anti-inflammatory cargo, such as microRNA-146a, which are functionalized in the lung microenvironment via ligand modification against specific receptors to deliver targeted genes. [Means for solving the problem]
[0005] EVs can be loaded with anti-inflammatory cargo and / or decorated with cell-targeting ligands, for example by transfecting plasmid DNA encoding specific cargo or ligands, as shown in Figure 1. The cargo can be refined depending on the inflammatory pathway that needs to be controlled, and the degree of surface decoration can be varied depending on the target cell type.
[0006] For example, type II alveolar epithelial cells and pulmonary macrophages can be targeted using plasmid genes encoding pulmonary surfactant protein A (SPA) and the membrane glycoprotein CD200, respectively. SPA-functionalized EVs interact with the receptor P63 / CKAP4 on type II cells, whereas CD200-functionalized EVs preferentially interact with the CD200R receptor in alveolar macrophages.
[0007] EVs are functionalized with SDF1, which interacts with the receptor CXCR7 in the pulmonary vasculature, which is useful for intravascular delivery of EVs, for example.
[0008] As shown in Figure 2, EVs after surface modification can also be loaded with anti-inflammatory cargo, which is a membrane-permeable pharmacological compound (e.g., Y-27632 Rho inhibitor, Calbiochem) that diffuses into the EVs due to a concentration gradient.
[0009] The details of one or more embodiments of the invention are set forth in the accompanying drawings and the accompanying claims. Other features, objects, and advantages of the invention will become apparent from the following description and drawings, and from the claims. [Brief description of the drawings]
[0010] [Figure 1] FIG. 1 is a schematic diagram showing the production of custom-made nanocarriers loaded with anti-inflammatory cargo and / or decorated with cell-targeting ligands following transfection of cells or tissues. [Diagram 2]FIG. 2 is a schematic showing EVs after surface modification with other anti-inflammatory cargo, e.g., membrane-permeable pharmacological compounds. [Figure 3A] Figures 3A to 3E show the characterization results of test tube derived designer EVs. Figures 3A and 3B show miR-146a loaded designer EVs isolated 24 hours after nanotransfection of primary mouse embryonic fibroblasts (PMEFs). The particle size was in the range of 200 nm and the EV concentration was in the range of billions of particles per mL. Figure 3C shows qRT-PCR characterization of miR-146A loaded designer EVs obtained from mouse dendritic cells 48 hours after nanotransfection with miR-146A encoding plasmid and mock / control plasmid (*p value=0.041). Figure 3D shows the relative expression of miR-146A in A549 lung epithelial cells and differentiated THP-1 monocytes treated with these miR-146A or mock designer EVs (*p value<0.001). In Figure 3E, we show C57BL / 6 mouse primary alveolar epithelial cells after treatment with fluorescently labeled miR-146a designer EVs derived from PMEFs for 48 h, with white arrows highlighting EV uptake. [Figure 3B] Same as above. [Figure 3C] Same as above. [Figure 3D] Same as above. [Figure 3E] Same as above. [Figure 3F] Same as above. [Figure 3G] Same as above. [Figure 3H] Same as above. [Figure 3I] Same as above. [Figure 4A]Figures 4A to 4F show the characterization of biogenic designer EVs. Figure 4A is a schematic of in vivo tissue nanotransfection (TNT) of skin and subsequent isolation of designer EVs. Figure 4B shows particle concentrations on the order of 10 trillion EVs per cm2 of skin. Figure 4C shows average particle sizes ranging from 109 to 135 nm. Figure 4D shows that both mock EVs and miR-146a designer EVs expressed positivity for the membrane EV marker tetraspanin CD9. Figure 4E shows qRT-PCR characterization of these biogenic miR-146a designer EVs, demonstrating their successful loading of molecular cargo. In vivo production of labeled designer EVs is shown in Figures 4F and 4G, where 24 hours after TNT of skin containing a plasmid encoding CD63-GFP (an EV tracer), GFP-labeled designer EVs are clearly produced by transfected skin cells (white arrows) compared to control tissue from non-transfected animals (Figure 4G). [Figure 4B] Same as above. [Figure 4C] Same as above. [Figure 4D] Same as above. [Figure 4E] Same as above. [Figure 4F] Same as above. [Figure 4G] Same as above. [Figure 5A] Figures 5A to 5F show that biogenic designer EVs modulate lung inflammation. After 4 hours of ventilation, miR-146A designer EVs improved physiological parameters (Figures 5A to 5D), significantly reduced BAL protein content (Figure 5E), and showed a trend toward reduced secretion of inflammatory cytokines (Figure 5F, *p-value = 0.022). [Figure 5B] Same as above. [Figure 5C] Same as above. [Figure 5D] Same as above. [Figure 5E] Same as above. [Figure 5F] Same as above. [Figure 6] In Figures 6A and 6B, we show functionalized designer EVs targeting inflamed lungs. Designer EVs can be functionalized to target various cellular compartments in the alveolar space. In vivo images of organs collected from animals treated for 24 hours with designer EVs functionalized with CD200 ligand to target alveolar macrophages are shown in Figure 6A. In Figure 6B, IF images of lung tissue treated with fluorescently labeled functionalized designer EVs after 24 hours are shown, showing an example of successful uptake (arrow). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0011] Disclosed herein are lung-targeted extracellular vesicles (EVs) loaded with anti-inflammatory cargo, as well as compositions, systems, and methods of making the same. The disclosed EVs include a lung-targeting ligand, such as a fusion protein that includes a lung-targeting moiety. Also disclosed are compositions including EVs that include the disclosed fusion proteins. In some embodiments, the EVs are loaded with anti-inflammatory cargo. Also disclosed are EV-producing cells designed to produce the disclosed EVs. Also disclosed are methods of producing the disclosed EVs, including culturing the disclosed EV-producing cells under conditions suitable for EV production. The methods further include a method of purifying EVs from the cells.
[0012] Before disclosing the present application in more detail, it should be noted that the disclosure of the present application is not limited to specific embodiments, which of course may be modified. It is also understood that the terms used in the present disclosure are used only to describe specific embodiments, and are not intended to be limiting, since the scope of the present disclosure is limited only by the scope of the appended claims.
[0013] For ranges of values described herein, values within the range are included in the disclosure to the tenth of the unit of the lower limit, unless the context clearly dictates otherwise, between the upper and lower limits of the range, or any other value or between within the described range. The upper and lower limits of narrower ranges may be independently included in the narrower ranges within the disclosure, and specific excluded limits may be provided in the described range. When a described range includes one or both limits, ranges excluding either or both are also included in the disclosure.
[0014] Unless otherwise defined, all technical and scientific terms used in this disclosure have the same meaning as commonly understood by those skilled in the art to which this disclosure pertains. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of this disclosure, the preferred methods and materials are described below.
[0015] All publications and patents cited in this disclosure are incorporated herein by reference as if each individual publication or patent was specifically and individually indicated to disclose and describe the methods and / or materials in connection with which the cited publications are incorporated by reference. Any cited publications are intended to be disclosed prior to the filing date of this application, but this should not be construed as an admission that the present disclosure is not entitled to antedate such publications. Further, the publication dates provided may be different from the actual publication dates, which may need to be confirmed independently.
[0016] As will be apparent to one of ordinary skill in the art upon reading this disclosure, the individual embodiments described and illustrated herein have distinct components and features which may be readily separated from or combined with any other features without departing from the scope or spirit of the disclosure. Any recited methods may be carried out in the order recited, or in any order which is logically made.
[0017] The embodiments of the present disclosure employ, unless otherwise indicated, chemical, biological and other techniques within the skill of the art.
[0018] The following examples are presented to fully disclose and describe to one of ordinary skill in the art the methods and uses disclosed and claimed herein. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.), but explanation for errors or deviations may be necessary. Unless otherwise indicated, units of materials are parts by weight, temperature is in degrees Celsius, and pressure is at or near atmospheric pressure. Standard temperature and pressure are defined as 20° C. and 1 atmosphere.
[0019] Before describing the embodiments of the present disclosure in detail, it should be noted that the present disclosure is not limited to particular materials, reagents, reaction materials, manufacturing processes, and the like, unless otherwise indicated, and may be modified. The terminology used in the present disclosure is for the purpose of describing particular embodiments only and is not intended to be limiting thereto. The present disclosure also allows steps to be performed in differing order where logical and consistent.
[0020] As used in this disclosure and the appended claims, when an object is referred to in the singular form "a," "an," and "the," the plural form is also intended to be included unless the context clearly indicates otherwise.
[0021] Disclosed EVs, in some embodiments, can be any that can be produced by cells. Cells secrete extracellular vesicles (EVs) with a wide range of diameters and functions, including apoptotic vesicles (1-5 μm), microvesicles (100-1000 nm in size), and vesicles of endosomal origin known as exosomes (50-150 nm).
[0022] The disclosed extracellular vesicles can be prepared by methods known in the art. For example, the disclosed extracellular vesicles can be prepared by expressing an mRNA encoding a cell-targeting ligand in a eukaryotic cell. In some embodiments, the cell also expresses an mRNA encoding an anti-inflammatory cargo. The mRNA for the cell-targeting ligand and the anti-inflammatory cargo can be expressed from a vector that is transfected into a production cell suitable for producing the disclosed EVs. The mRNA for the cell-targeting ligand and the anti-inflammatory cargo can be expressed from the same vector (e.g., where the vector expresses the mRNA for the cell-targeting ligand and the anti-inflammatory cargo from separate promoters), or the mRNA for the cell-targeting ligand and the anti-inflammatory cargo can be expressed from separate vectors. The vector or vectors expressing the mRNA for the cell-targeting ligand and the anti-inflammatory cargo can be packaged in a kit designed for the preparation of the disclosed extracellular vesicles.
[0023] Also disclosed are compositions comprising EVs having the disclosed targeting ligands. In some embodiments, the EVs are loaded with the disclosed anti-inflammatory cargo. Also disclosed are EV-producing cells engineered to secrete the disclosed EVs.
[0024] EVs, such as exosomes, are produced by many different types of cells, including B lymphocytes, T lymphocytes, dendritic cells (DCs) and most cellular immune cells. EVs are also produced, for example, by glioma cells, platelets, reticulocytes, neurons, intestinal epithelial cells, and tumor cells. The EVs used in the disclosed compositions and methods can be derived from any suitable cells, including the specific cells listed above. Non-limiting examples of EV-producing cells suitable for mass production include dendritic cells (e.g., immature dendritic cells), human embryonic kidney 293 (HEK) cells, 293T cells, Chinese hamster ovary (CHO) cells, and human ESC-derived mesenchymal stem cells. EVs can also be obtained from autologous patient-derived, allogeneic haplotype-compatible stem cells, or allogeneic stem cells, so that the occurrence of an immune response in the patient to which the exosomes are introduced can be reduced or avoided. Any EV-producing cell can be used for this purpose.
[0025] Also disclosed are methods of loading the disclosed EVs with anti-inflammatory cargo, comprising engineering the disclosed EVs to secrete and culturing the disclosed EV-producing cells, the method further comprising purifying the EVs from the cells.
[0026] EVs produced from cells can be collected from the medium by any suitable method. Typically, EVs can be prepared from cell culture or tissue supernatants by centrifugation, filtration, or a combination of these methods. For example, EVs can be prepared by centrifugation at low speed (<20,000g) to obtain larger particle spherical EVs, followed by centrifugation at high speed (>100,000g) for spherification of EVs, size filtration using a suitable filter, gradient ultracentrifugation (e.g., using a sucrose gradient), or a combination of these methods.
[0027] The disclosed EVs are expressed on the surface of lung cells in the lung and are targeted by the expression of a targeting moiety that binds to the cell surface. Suitable examples of targeting moieties include short peptides, scFvs and complete proteins, provided that the targeting moiety is expressed on the surface of exosomes. Peptide targeting moieties are usually less than 100 amino acids in length, e.g., less than 50 amino acids, less than 30 amino acids, and may have a minimum length of 10, 5 or 3 amino acids.
[0028] In some embodiments, type II alveolar epithelial cells can be targeted by the use of pulmonary surfactant protein A (SPA). EVs functionalized with SPA interact with the receptor P63 / CKAP4 on type II cells. In some embodiments, the targeting moiety is SPA1, which has the following amino acid sequence: MWLCPLALNLILMAASGAVCEVKDVCVGTPGIPGECGEKGEPGERGPPGLPAHLDEELQATLHDFRHQILQTRGALSLQGSIMTVGEKVFSSNGQSITFDAIQEACARAGGRIAVPRNPEENEAIASFVKKYNTYAYVGLTEGPSPGDFRYSDGTPVNYTNWYRGEPAGRGKEQCVEMYTDG QWNDRNCLYSRLTICEF (SEQ ID NO: 1) or variants and / or fragments thereof having at least the following identity to SEQ ID NO: 1 that can interact with the receptor P63 / CKAP4 on type II cells: 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%.
[0029] In some embodiments, the targeting ligand is a fragment of SPA1 and is at least , 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, or 199 consecutive amino acids of SEQ ID NO:1 or a variant thereof.
[0030] In some embodiments, the targeting moiety is a SPA2 moiety having the following amino acid sequence:MWLCPLALTLILMAASGAACEVKDVCVGSPGIPGTPGSHGLPGRDGRDGVKGDPGPPGPMGPPGETPCPPGNNGLPGAPGVPGERGEKGEAGERGPPGLPAHLDEELQATLHDFRHQILQTRGALSLQGSIMTVGEKVFSSNGQSITFDAIQEACARAGGRIAVPRNPEENEAIASFVKKYNTYAYVGLTEGPSPGDFRYSDGTP VNYTNWYRGEPAGRGKEQCVEMYTDGQWNDRNCLYSRLTICEF (SEQ ID NO: 2) or a variant and / or fragment thereof having at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity to SEQ ID NO: 2 that is capable of interacting with the receptor P63 / CKAP4 on type II cells.
[0031] In some embodiments, the targeting ligand is a fragment of SPA2 and is at least 91, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 2 24, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, or 248 consecutive amino acids of SEQ ID NO:2 or a variant thereof.
[0032] In some embodiments, lung macrophages can be targeted using the membrane glycoprotein CD200. EVs functionalized with CD200 preferentially interact with the CD200R receptor in alveolar macrophages. In some embodiments, the targeting moiety is CD200 with the following amino acid sequence 3: MERLVIRMPFCHLSTYSLVWVMAAVVLCTAQVQVVTQDEREQLYTPASLKCSLQNAQEALIVTWQKKKAVSPENMVTFSENHGVVIQPAYKDKINITQLGLQNSTITFWNITLEDEGCYMCLFNTFGFGKISGTACLTVYVQPIVSLHYKFSEDHLNITCSATARPAPMVFWKVPRSGIENSTVTLSHPNGTTSVTSILHIKDPKNQVGKE VICQVLHLGTVTDFKQTVNKGYWFSVPLLLSIVSLVILLVLISILLYWKRHRNQDREP (SEQ ID NO: 3) or variants thereof and / or fragments thereof having at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity to SEQ ID NO: 3 that are capable of interacting with pulmonary macrophages.
[0033] In some embodiments, the targeting ligand is a fragment of CD200 and is at least 100, 110, 120, 130, 140, 141, 142, 143, 144, 145, 156, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 20A, 209, 2010, 2011, 2012, 209, 2013, 209, 2014, 209, 2015, 2016, 2017, 2018, 2019, 210, 210, 211, 212, 213, 214, 215, 3, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201 , 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, or 269 consecutive amino acids of SEQ ID NO:3 or a variant thereof.
[0034] In some cases, cell-targeting ligands can be expressed on the surface of EVs as fusion proteins with exosomal or lysosomal transmembrane proteins. Many proteins are known to be associated with exosomes; that is, they are incorporated into exosomes. Examples include, but are not limited to, Lamp-1, Lamp-2, CD13, CD86, flotillin, syntaxin-3, CD2, CD36, CD40, Cd40l, CD41a, CD44, CD45, ICAM-1, Integrin alpha4, LiCAM, LFA-1, Mac-1 alpha and beta, Vti-IA and B, CD3 epsilon and zeta, CD9, CD18, CD37, CD53, CD63, CD81, CD82, CXCR4, FcR, GluR2 / 3, HLA-DM (MHC II), immunoglobulins, MHC-I or MHC-II components, TCR beta, and tetraspanins.
[0035] The disclosed extracellular vesicles can further be loaded with anti-inflammatory agents, which transport the anti-inflammatory agents to target cells. Suitable anti-inflammatory agents include, but are not limited to, therapeutic agents (e.g., small molecule drugs), therapeutic proteins, and therapeutic nucleic acids (e.g., therapeutic RNAs). In some embodiments, the disclosed extracellular vesicles include a therapeutic RNA (also referred to as "cargo RNA" in the present disclosure). For example, in some embodiments, a fusion protein further comprising a cell-targeting motif includes an RNA domain (e.g., at the cytosolic C-terminus of the fusion protein) that binds to one or more RNA motifs present in the cargo RNA for the purpose of packaging the cargo RNA into the extracellular vesicle prior to secretion of the extracellular vesicle from the cell. In this way, the fusion protein can function as both a "cell-targeting protein" and a "packaging protein". In some embodiments, the packaging protein is referred to as an extracellular vesicle-loading protein or an "EV-loading protein".
[0036] In some embodiments, the cargo RNA is miRNA, shRNA, mRNA, ncRNA, sgRNA, or any combination thereof. For example, in some embodiments, the anti-inflammatory agent is microRNA 146a.
[0037] Additional anti-inflammatory microRNAs that can be used include miR-155, miR-9, miR-210, miR-146b, and miR-181. Anti-inflammatory miR-155, miR-9, miR-210, and miR-146b have been shown to be upregulated during high tidal volume ventilation and acute lung injury (ALI), induced lung injury (VILI), and osteoarthritis in mouse models of ALI / ARDS. Meanwhile, MiR-181 regulates the inflammatory response of macrophages via IL-1α. MiR-9, miR-511, miR-146a, miR-23b, and miR-181a have been previously reported as anti-inflammatory miRNAs that are upregulated in the lung, especially during sepsis and ARDS.
[0038] Designer EVs can also be used to efficiently deliver key growth factors, regulatory proteins, and anti-inflammatory cytokines to reduce lung inflammation and injury, as well as enhance tissue repair during ARDS / VILI. For example, they can be loaded with the anti-inflammatory cytokines interleukin-10 and interleukin-4, the regulatory proteins secreted leukocyte protease inhibitor (SLPI), and keratinocyte growth factor (KGF), which have been shown to reduce ARDS-induced mortality and modulate inflammation.
[0039] The length of the cargo RNA of the disclosed extracellular vesicles may be any suitable length. For example, in some embodiments, the cargo RNA may have a nucleotide length of at least about 10 nt, 20 nt, 30 nt, 40 nt, 50 nt, 100 nt, 200 nt, 500 nt, 1000 nt, 2000 nt, 5000 nt or more. In other embodiments, the cargo RNA may have a nucleotide length of about 5000 nt, 2000 nt, 1000 nt, 500 nt, 200 nt, 100 nt, 50 nt, 40 nt, 30 nt, 20 nt, or 10 nt or less. In further embodiments, the cargo RNA may have a nucleotide length within these designed nucleotide lengths, for example, a nucleotide length ranging from about 10 nt to 5000 nt, or other ranges. The cargo RNA of the disclosed extracellular vesicles may be relatively long, for example, when the cargo RNA comprises an mRNA or another relatively long RNA.
[0040] In some embodiments, the anti-inflammatory cargo is a membrane-permeable pharmacological compound that is secreted by cells and then loaded onto EVs. For example, in some embodiments, the anti-inflammatory cargo includes Y-27632 Rho inhibitor (Calbiochem), which can diffuse into EVs via a concentration gradient (see FIG. 2).
[0041] According to the disclosed method, clinically relevant lipophilic compounds and other anti-inflammatory membrane-permeable compounds can be loaded into EVs. One example of this type of compound is statins, more specifically simvastatin, which is used in clinical settings to lower cholesterol levels in the blood. Simvastatin can be effectively delivered locally to inflamed lungs via designer EVs to suppress inflammation and help speed up recovery in patients with, for example, ALI / ARDS or VILI.
[0042] In some embodiments, the anti-inflammatory cargo is loaded onto the EVs by diffusion down a concentration gradient.
[0043] The present disclosure also describes a method of using EVs. For example, the disclosed extracellular vesicles may be used to deliver the disclosed anti-inflammatory cargo to target lung cells, which method includes contacting the target cells with the disclosed EVs. Thus, the present disclosure also includes a method of treating a lung disease in a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising the disclosed cargo-loaded lung-targeted EVs. In some embodiments, the subject develops ARDS.
[0044] The disclosed designer EVs can be used to modulate a wide variety of inflammatory conditions in different organ systems, not just the lung, essentially by designing ligands for EV modification, including ventilator-induced lung injury (VILI), pulmonary fibrosis, and infections such as sepsis, influenza, and pneumonia.
[0045] The disclosed EVs may be formulated as part of a pharmaceutical composition for the treatment of a pulmonary disease or disorder, and the pharmaceutical composition can be administered to a patient in need thereof to deliver the cargo to targeted lung cells in treating the pulmonary disease or disorder.
[0046] The disclosed EVs can be administered to a subject by any suitable means. The mode of administration to a subject, such as a human or animal, can be selected from parenteral, intramuscular, intracerebral, intravascular, subcutaneous, or transdermal administration. Typically, the delivery method is by injection. Preferably, the injection is intramuscular or intravascular (e.g., intravenous). A physician can determine the required administration route for each particular patient.
[0047] The EV is preferably introduced as a composition. The composition can be formulated for parenteral, intramuscular, intracerebral, intravascular (including intravenous), subcutaneous, or transdermal administration. Compositions for parenteral administration include sterile aqueous solutions that also contain buffers, diluents, and other suitable additives. The EV may also be formulated as a pharmaceutical composition that additionally includes pharma- ceutically acceptable carriers, thickeners, diluents, buffers, preservatives, and other pharma-ceutically acceptable carriers or excipients.
[0048] Parenteral administration is generally characterized by injection, such as subcutaneous, intramuscular, or intravenous. Preparations for parenteral administration include lyophilized powders, including sterile solutions for injection and subcutaneous tablets, sterile suspensions for injection, and even sterile dry insoluble products for injection, combined with vehicles and sterile emulsions immediately prior to use. Solutions can be either aqueous or non-aqueous.
[0049] Suitable carriers for intravenous administration include solutions containing saline or phosphate buffered saline (PBS), as well as thickening and solubilizing agents such as glucose, polyethylene glycol, and polypropylene glycol, and mixtures thereof. Pharmaceutically acceptable carriers for use in parenteral formulations include aqueous vehicles, non-aqueous vehicles, antibacterial agents, isotonic agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, emulsifying agents, sequestering or chelating agents, and other pharma- ceutically acceptable substances. Aqueous vehicles include, for example, sodium chloride injection, Ringer's injection, isotonic dextrose injection, sterile water injection, dextrose and lactated Ringer's injection. Non-aqueous parenteral vehicles include fatty oils derived from plants, cottonseed oil, corn oil, sesame oil, and peanut oil. Antimicrobial agents should be added to parenteral preparations packaged in multiple dose containers, including phenol or cresol, mercurial, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoic acid esters, thimerosal, benzalkonium chloride, and benzethonium chloride, in concentrations that will produce bacteriostatic or fungistatic properties. Isotonic agents include sodium chloride and dextrose. Buffers include phosphates and citrates. Antioxidants include sodium bisulfate. Local anesthetics include procaine hydrochloride. Suspending and dispersing agents include sodium carboxymethylcellulose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone.
[0050] Emulsifying agents include polysorbate 80 (TWEEN® 80). Sequestering or chelating agents for metal ions include EDTA. Pharmaceutical carriers include ethyl alcohol, polyethylene glycol, and propylene glycol for water-miscible vehicles, sodium hydroxide, hydrochloric acid, citric acid, or lactic acid for pH adjustment. The concentration of the pharmacoactive compound is adjusted to an effective amount to produce the desired pharmacological effect upon injection. The exact dose depends on the age, weight, and condition of the patient or animal, as is known in the art.
[0051] Unit dose parenteral preparations can be filled into ampoules, vials, or syringes with needles. All preparations to be used for parenteral administration must be sterile, as is conventionally practiced in the art.
[0052] The compositions are administered in therapeutically effective amounts. The dosage may be determined according to a variety of factors, particularly the severity, age, and weight of the patient being treated; the route of administration; and the required regimen. The route of administration and dosage required for a particular patient are determined by the physician. The optimal dosage may vary depending on the relative potency of the individual components, but can generally be estimated based on the EC50 found to be effective in in vitro and in vivo animal models. Dosages are generally between 0.01 mg and 100 mg per kg of body weight. A typical daily dosage is about 0.1 to 50 mg per kg of body weight, preferably about 0.1 mg / kg to 10 mg / kg, depending on the potency of the particular component, the age, weight, and condition of the subject being treated, the severity of the disease, and the frequency and route of administration. Different dosages of the components are administered depending on whether administration is by intramuscular or systemic (intravenous or subcutaneous) injection.
[0053] The dosage for a single intramuscular injection is preferably in the range of about 5 to 20 μg. The dosage for single or multiple systemic injections is preferably in the range of 10 to 100 mg / kg of body weight.
[0054] Due to clearance of the construct (and degradation of any target molecule), the patient may need to undergo repeated treatment, for example, daily, weekly, monthly, or one or more times per year. Those skilled in the art can easily estimate the number of repeated doses based on the residence time and concentration of the construct in bodily fluids or tissues. Even after successful treatment, it may be desirable to subject the patient to maintenance therapy, in which case the construct is administered at a maintenance dose ranging from 0.01 mg / kg to 100 mg / kg of body weight, once or more per day to once every 20 years.
[0055] Although a number of embodiments of the present invention have been described, various modifications can be made without departing from the spirit and scope of the present invention, provided that such embodiments are encompassed by the following claims. EXAMPLES
[0056] Example 1 Figure 3 shows the characterization and transduction results of designer EVs derived from living organisms. Figure 3A shows a bar graph characterizing miR-146a and SH-loaded EVs via qRT-PCR. SH-CT or miR-loaded EVs were delivered via an intubation tube inserted into the trachea prior to ventilation. Figure 3B shows a bar graph of physiological measurements in animals treated with SH-CT or miR-146A-loaded EVs (MV protocol: tidal volume 12cc / kg, respiratory rate 150 breaths / min, positive end-expiratory pressure under 0 cm H2O for 4 h). Figure 3C shows a bar graph of the change in BAL protein content in animals treated with SH and miR-146a after 4 h of MV. Figure 3D shows a bar graph of the average size distribution of EVs loaded with mock plasmid (sham control-SH) or anti-inflammatory miR-146a.
[0057] Anti-inflammatory miR-146a-loaded bioderived designer EVs were obtained by nanotransfecting the dorsal skin of C57BL6 mice (8–10 weeks old) with a plasmid encoding miR-146a (OriGene). 24 h after skin transfection, loaded EVs were collected from skin biopsies and isolated with an ExoQuick kit (SystemBio). After isolation, EVs were kept granular and suspended in 0.9% sodium chloride solution for subsequent use. EV loading efficiency was measured by quantifying the copy number of miR-146a via qRT-PCR.
[0058] Designer EVs were evaluated in vivo. Briefly, mechanical ventilation (MV) was performed according to a previously published ventilation protocol that can induce significant lung injury. The conditions were tidal volume 12cc / kg, respiratory rate 120 breaths / min, and positive end-expiratory pressure under 0 cmH2O for 4 h. In these experiments, designer EVs were introduced into the lungs of these mice via intratracheal injection (using 2 μL / g mouse weight) prior to MV. Lung physiology and oxygen saturation data were collected during the ventilation process. After 4 h, the animals were euthanized and bronchoalveolar lavage (BAL) data and tissues were collected.
[0059] Example 2: In vitro approach to producing designer EVs Nanochannel-based electroporation was used to overexpress the cargo of interest in donor cells within a controlled range, allowing the content and degree of surface modification of EVs to be set in the desired range. Nanochannel-based electroporation allowed transfection efficiency and cell viability to be up to 100% and was not limited by capsid size. Using this approach, we obtained designer EVs loaded with anti-inflammatory miR-146A from multiple cell sources, including primary cultures of mouse dendritic cells and embryonic fibroblasts, as well as human cell lines (Figure 3A-3E). Characterization results of EV content showed successful uptake of the molecular cargo of interest compared to mock-loaded EVs (Figure 3C). Such EVs were then effectively used to modulate gene expression in cultures of human lung epithelial cells and human macrophages (Figure 3D). Designer EVs loaded with the proneural factor genes ASCL1, BRN2, and MYT1l (ABM) were also obtained from early primary cultures of mouse fibroblasts. Dynamic release and uptake of ABM-loaded designer EVs revealed that EV release from donor cells peaked 24 h after transfection, with concentrations on the order of billions of particles / ml. The copy numbers of genes loaded into EVs exceeded the original copy numbers delivered to the "donor" cells by approximately three orders of magnitude, suggesting that the therapeutic cargo is amplified intracellularly prior to EV release.
[0060] Example 3: In vivo approach to producing designer EVs Nanochannel-based tissue transfection to induce designer EVs from in vivo tissues could conceivably enable the use of a patient's own tissue as a mass-produced EV bioreactor, with important clinical and production implications. 2 Approximately 10 trillion EVs carrying the anti-inflammatory miR-146A can be obtained from mouse skin (Figure 4). By effectively utilizing such EVs, inflammation induced by mechanical ventilation can be suppressed (Figure 5).
[0061] Example 3: Given the need for critical care, prolonged hospital stays, and delayed recovery, ARDS places a significant burden on the healthcare system. According to the American Lung Association (2013), approximately 190,000 cases of ARDS occur annually in the United States. Mortality in ARDS patients is high, reaching 38-45%. ARDS is usually caused by blunt trauma to the lungs or an underlying condition such as sepsis. Once the lungs are damaged, they can develop life-threatening sepsis accompanied by a severe systemic inflammatory response caused by infection, which has led to the deaths of many ICU patients. ARDS is characterized by severe hypoxia, impaired alveolar-capillary barrier function, small airway flooding due to reduced production of pulmonary surfactant, and activation of proinflammatory pathways. While mechanical ventilation supports oxygen therapy, mechanical stress can exacerbate the initial injury and lead to ventilator-induced lung injury (VILI), which is associated with a higher mortality rate. All these factors further exacerbate the underlying lung injury, promoting inflammation and encouraging a positive feedback loop that may lead to multiple organ failure and death. Currently, there is no cure for ARDS, but promising approaches using lung-targeted anti-inflammatory cargoes are promising. Cell-based (e.g., endothelial progenitor cells, mesenchymal stem cells) therapies can, for example, reduce inflammation and promote lung repair via trophic and anti-inflammatory / infective mechanisms. However, significant concerns remain regarding the safety of progenitor-based cell therapies, which may lead to tumor formation and hyperimmunogenic responses, in part due to excessive ex vivo processing. While the identity of certain therapeutic agents has been elucidated, how to efficiently deliver therapeutic agents to the inflamed lung remains a major challenge for critically ill patients. Key to overcoming these limitations are anti-inflammatory and antimicrobial molecular cargoes, which can be efficiently and selectively delivered by functionalized designer EVs to reduce lung inflammation and injury and enhance tissue repair during sepsis-induced ARDS. Table 1 shows the design details of designer EVs loaded with molecular cargo. [Table 1]
[0062] We optimized the experimental protocol to obtain designer EVs derived from living tissues. In this focus area, we obtained designer EVs loaded with anti-inflammatory or antibacterial cargos by in vivo nanotransfection of plasmids encoding each factor into the skin of 8-10 week-old C57BL6 mice, as described in Table 1. The tissue nanotransfection platform was fabricated in a clean room by a combination of projection / contact photolithography and deep-drilling reactive ion etching, as previously reported. EVs were collected from skin biopsies at different time points after transfection. To isolate EVs, skin samples were dissociated and homogenized using gentleMACS dissociation agent. EVs were selectively precipitated using a Total Exosome Isolation Kit and stored at -80 °C for later use.
[0063] Designer EVs are functionalized for targeted delivery to the pulmonary epithelial and macrophage cellular compartments, which are key hubs of ARDS inflammation. Functionalized designer EVs are obtained by nanotransfection with plasmids for pulmonary surfactant protein A (SPA) and the membrane glycoprotein CD200 (Figure 6). SPA-functionalized EVs interact with the receptor p63 / CKAP4 on alveolar lung cells and also bind toll-like receptor-2 (TLR2) on these cells, which is expected to attenuate the activation of the NFκβ inflammatory pathway. EVs functionalized with CD200 tend to preferentially interact with the CD200R receptor on alveolar macrophages, which modulates the proinflammatory state. Additional endothelial-targeting ligands were used in combination with SPA and CD200 to facilitate the interaction of designer EVs delivered via the systemic circulation with the pulmonary microvasculature. EVs co-functionalized with the SDF1 ligand preferentially interact with the CXCR7 receptor on the pulmonary vasculature. This facilitates their upregulation under injury conditions and subsequent anchoring to the pulmonary vasculature as designer EVs migrate to the alveolar space. Identifying the optimal route of administration of designer EVs is also a key step in optimizing designer EVs for therapeutic applications. Therefore, we compared three non-invasive routes of administration (Table 2) to determine the best delivery method for therapeutic applications. [Table 2]
[0064] For each delivery method, dose sensitivity analyses were performed on healthy and diseased animals treated with functional and non-functional anti-inflammatory, antibacterial, or mock designer EVs (Table 3). In this analysis, bronchoalveolar lavage specimens (BAL), blood, and lungs are collected and the relative expression of genes encoding the delivered molecular cargo, as well as key pro- and anti-inflammatory factors (Table 4), are quantified via qRT-PCR. This analysis determines the optimal dose concentration to significantly modulate lung inflammation in vivo. These results are correlated with the area of transfected skin required to obtain an optimal concentration of designer EVs. Accumulation and clearance of off-target moieties are tested based on quantitative biodistribution studies (Figure 6). [Table 3] [Table 4]
[0065] In addition to in vivo studies, extensive in vitro characterization of EVs will provide a better understanding of their nature. This includes the analysis of size distribution, charge, and particle concentration as a function of cargo and surface modification, for example, using Nanosight and Zeta Potential Analyzer systems. EV loading efficiency is determined by quantifying the copy number of each gene packaged per EV using an absolute quantitative qRT-PCR protocol derived from standard curves generated for each plasmid DNA. These results correlate with the copy number transfected in the skin. Total RNA sequencing is used to characterize the content of designer EVs loaded with anti-inflammatory, antibacterial, or pseudomolecule cargo, thus providing detailed information on the morphology of coding and non-coding RNA packaged within designer EVs. Furthermore, comparative proteomic analysis (at membrane and cytosolic levels) of functional and non-functional designer EVs will be performed to determine the efficiency of packaging of anti-inflammatory and antibacterial molecular cargo, as well as the efficiency of membrane ligand expression.
[0066] To better understand the mechanism of action of designer EVs, in vivo performance evaluation results in a mouse model of lung injury (Table 3) were taken as a benchmark against well-established test tube models of injury (Table 5). Test tube models allow for effective and systematic study of designer EVs on specific cell populations, while in vivo models allow for a better understanding of responses under pathophysiological conditions where interactions between multiple organ systems are important. In vivo, the efficacy of designer EVs in reducing inflammation and bacterial infection was evaluated using a mouse model of sepsis-induced ARDS and a two-hit model. These models help determine the potential impact of observed levels of inflammation attenuation from a specific concentration of designer EVs under infection. Using test tube models of barotrauma and volutrauma, designer EVs were probed on cellular components isolated from lung tissue and bacterial cultures. [Table 5]
[0067] For in vivo injury models, designer EVs were administered at various doses (e.g., single vs. repeated) and time points (e.g., pre-injury vs. post-injury) (Table 2). To model sepsis-induced ARDS, 8-10 week-old C57BL6 mice were subjected to cecal ligation and puncture (CLP) or sham laparotomy. Pulmonary edema was assessed after CLP from ultrasound imaging with a Vevo2100 system. Animals were sacrificed, and BAL, blood, and major organs (i.e., lungs, heart, spleen, liver, and kidneys) were collected after perfusion with sterile saline for downstream analysis. The use of a two-hit model allows for the reproduction of a more clinically relevant condition, such as when infected patients require mechanical ventilation. In this model, 8-10 week old C57BL6 mice were first subjected to CLP or sham laparotomy and then 24 hours after CLP, exposed to mechanical ventilation under noxious protocol conditions (tidal volume 12cc / kg, 120 breaths / min, and positive end-expiratory pressure under 0 cm H2O for 4 hours using FlexiVent FX, SCIREQ). Lung physiology and oxygen saturation data were collected during the MV course, and at the end of MV, animals were sacrificed by anesthetic overdose and BAL, blood, and major organs were collected after perfusion with sterile saline for downstream analysis. Cellular content of BAL samples was determined by inflammatory cell counts (i.e., alveolar macrophages, lymphocytes, eosinophils, neutrophils, and mast cells). BAL protein content was also measured because elevated protein content correlates with loss of alveolar-capillary barrier function integrity. After protein quantification, all BAL and plasma samples were screened for expression of pro- and anti-inflammatory cytokines and factors using a custom-made cytokine array (Table 4). The relative expression of the molecular cargo introduced in vivo (relative to the treatments listed in Table 1) and the effect of these treatments on the expression of key anti- and pro-inflammatory molecular markers (listed in Table 4) were assessed via qRT-PCR.
[0068] For the in vivo injury model, co-cultures of primary lung epithelial cells and mouse-derived macrophages are subjected to barotrauma or volumetric injury. Barotrauma is induced using a previously published cyclic pressure model. For this, cells were co-cultured on transwell inserts and the apical compartment was pressurized for 24 h to apply cyclic oscillatory pressures of 0–20 cm H2O at a frequency of 0.2 Hz, simulating the same conditions as those observed in a ventilator and normal respiratory rate. Volumetric injury was simulated using the FlexcellFX-5000 tension system. In this model, cells were co-cultured on modified 6-well plates with elastomeric bottoms and subjected to continuous and cyclic stretching at 10–20% elongation at 1.25 Hz for 24 h in a cell culture incubator. Secretion of key proinflammatory molecules (Table 4) into the medium was monitored. To assess the formation and retention of tight junctions, ZO-1 was stained and imaged via IF as an indicator of epithelial-endothelial barrier function after trauma. The experimental groups employed in this evaluation are shown in Table 5.
[0069] Unless otherwise specified, all technical and scientific terms used in this disclosure have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosure pertains. Publications and cited materials cited in this disclosure are incorporated herein by reference.
[0070] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein which are intended to be encompassed by the following claims.
Claims
1. 1. A method for treating acute respiratory distress syndrome (ARDS), comprising: producing said therapeutic extracellular vesicles by nanotransfecting skin cells with a non-viral vector encoding a fusion protein comprising pulmonary surfactant protein A (SPA) and a heterologous exosomal or lysosomal transmembrane protein under conditions suitable for secretion of the vesicles; and collecting the extracellular vesicles produced by said skin cells; the therapeutic extracellular vesicles are loaded with a therapeutic cargo; the therapeutic cargo comprises miR146a or Y-27632; and The therapeutic extracellular vesicle, wherein the method comprises administering the therapeutic extracellular vesicle to a patient with ARDS.
2. The therapeutic extracellular vesicles of claim 1, produced by nanotransfecting skin cells with a non-viral vector encoding a fusion protein comprising pulmonary surfactant protein A (SPA) and a heterologous exosomal or lysosomal transmembrane protein under conditions suitable for secretion of the vesicles, and collecting the extracellular vesicles produced in the skin cells.
3. Therapeutic extracellular vesicles derived from skin cells expressing a lung-targeted fusion protein comprising pulmonary surfactant protein A (SPA) and a heterologous exosomal or lysosomal transmembrane protein, and carrying a therapeutic cargo comprising miR146a or Y-27632.
4. The therapeutic extracellular vesicle of claim 3, wherein the therapeutic cargo comprises miR146a.
Citation Information
Patent Citations
Exosomes useful to treat cystic fibrosis
WO2017075708A1
Extracellular vesicle comprising a fusion protein having FC binding capacity
WO2018015535A1
